These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17244172)

  • 21. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonergic approaches in the development of novel antipsychotics.
    Jones CA; McCreary AC
    Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological treatment of negative symptoms in schizophrenia.
    Möller HJ; Czobor P
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):567-78. PubMed ID: 25895634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
    Altamura AC; Bobo WV; Meltzer HY
    Int Clin Psychopharmacol; 2007 Sep; 22(5):249-67. PubMed ID: 17690594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia.
    Friedman JI; Carpenter D; Lu J; Fan J; Tang CY; White L; Parrella M; Bowler S; Elbaz Z; Flanagan L; Harvey PD
    J Clin Psychopharmacol; 2008 Feb; 28(1):59-63. PubMed ID: 18204342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential lower efficacy of molindone among first-generation antipsychotics.
    Waugaman RM
    Am J Psychiatry; 2009 Apr; 166(4):491; author reply 492-3. PubMed ID: 19339370
    [No Abstract]   [Full Text] [Related]  

  • 30. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
    Newman-Tancredi A; Cussac D; Depoortere R
    Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
    Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of schizophrenia negative symptoms: future prospects.
    Erhart SM; Marder SR; Carpenter WT
    Schizophr Bull; 2006 Apr; 32(2):234-7. PubMed ID: 16492797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Longterm treatment of schizophrenia].
    Pajonk VF
    MMW Fortschr Med; 2006 Jan; 148(4):35-8. PubMed ID: 16502798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.